Trial · NCT02037347
Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
NCT02037347, Phase 1, Phase 2, Terminated, Brett King; results first posted 2016-11-30
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis. Trials, record NCT02037347. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT02037347
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- Study to Evaluate the Use of Palifermin to Treat Toxic Epidermal Necrolysis
- NCT number
- NCT02037347
- Status
- Terminated
- Phases
- Phase 1, Phase 2
- Enrollment
- 1 participants, actual
- Lead sponsor
- Brett King
- Conditions
- Toxic Epidermal Necrolysis, Stevens-Johnson Syndrome
- Interventions
- Palifermin
- First posted
- 2014-01-15
- Last updated
- 2016-11-30
- Results first posted
- 2016-11-30
Source ClinicalTrials.gov
Registered outcomes3
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Time-to-cutaneous Re-epithelialization | The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days | |
| Secondary | Time-to-mucosal Re-epithelialization | The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days | |
| Secondary | Time-to-cessation of Epidermal Necrosis | The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days |
Source ClinicalTrials.gov
Outcomes3
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
| Type | Outcome | Time frame | Population | Units | Measured as |
|---|---|---|---|---|---|
| PRIMARY | Time-to-cutaneous Re-epithelialization | The number of days between the start of palifermin administration and complete re-epithelialization of skin up to 14 days | days | NUMBER | |
| SECONDARY | Time-to-mucosal Re-epithelialization | The number of days between the start of palifermin administration and complete re-epithelialization of oral mucosa up to 14 days | Adverse event experienced by participant precluded measuring this outcome. | ||
| SECONDARY | Time-to-cessation of Epidermal Necrosis | The number of days between the start of palifermin administration and cessation of further epidermal necrosis up to 14 days | days | NUMBER |
Source ClinicalTrials.gov
Results by group2
Each measurement the trial posted, group by group, in the words and numbers it posted.
| Outcome | Group | Category | Value | Spread | Units |
|---|---|---|---|---|---|
| Time-to-cutaneous Re-epithelialization | Palifermin | 6 | days | ||
| Time-to-cessation of Epidermal Necrosis | Palifermin | 3 | days |
Source ClinicalTrials.gov
Participant flow3
How many started, completed or left each group, period by period.
| Period | Milestone | Group | Participants | Units counted |
|---|---|---|---|---|
| Overall Study | STARTED | Palifermin | 1 | |
| Overall Study | COMPLETED | Palifermin | 1 | |
| Overall Study | NOT COMPLETED | Palifermin | 0 |
Source ClinicalTrials.gov
Adverse events1
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
| Type | Event | Organ system | Group | Affected | At risk | Events |
|---|---|---|---|---|---|---|
| serious | ischemic necrosis | Gastrointestinal disorders | Palifermin | 1 | 1 |
Source ClinicalTrials.gov
Adverse event totals3
The totals the trial posted for each group.
| Total | Group | Affected | At risk |
|---|---|---|---|
| Total, all-cause mortality | Palifermin | ||
| Total, other adverse events | Palifermin | 0 | 1 |
| Total, serious adverse events | Palifermin | 1 | 1 |
Source ClinicalTrials.gov
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT02037347
GET https://conductscience.org/api/trials/v1/NCT02037347/registered